In order to investigate the relationship between COO classification, MYC/BCL-2 status, and replicative/oxidative stress biomarkers, we first profiled two independent case series of chemoimmunotherapy-treated DLBCL with T-GEP, FISH, and immunohistochemistry: a discovery cohort from the DLC04 study [34], and a validation cohort of patients treated in real-life clinical practice. Here, BCL2 is linked to diffuse large B-cell lymphoma.